[Gln22,Asn23]-beta-Amyloid (1-40), Dutch/Iowa double mutation – 0.5 mg

Overview

The [Gln22,Asn23]-beta-Amyloid (1-40), Dutch/Iowa double mutation is a vital peptide for researchers investigating the mechanisms of Alzheimer’s Disease. The E22Q/D23N variant demonstrates increased potency compared to single mutant forms, making it essential for studies focused on its pathologic responses. This peptide rapidly assembles in solution, forming fibrils that are integral to the progression of Alzheimer’s. By utilizing this double-mutant form, you’ll gain deeper insights into the biological impact of beta-amyloid and the underlying factors contributing to neurodegenerative diseases.

Key Features

• Contains the double mutation E22Q/D23N, enhancing pathogenic properties
• More potent than single mutant forms for research on Alzheimer’s Disease
• Rapidly forms fibrils in solution, crucial for studying fibrillogenesis
• Available in 0.5 mg for flexibility in various applications
• Part of a comprehensive catalog of peptides, including options like Autocamtide-2 and CREBtide

Specifications

FAQ

What is the significance of the E22Q/D23N mutation?

The E22Q/D23N mutation significantly enhances the fibrillogenic properties of beta-amyloid, which can lead to more pronounced pathologic responses in Alzheimer’s studies.

How should I store this peptide?

It’s recommended to store the [Gln22,Asn23]-beta-Amyloid peptide at -20°C or lower to maintain its stability and integrity for effective research applications.

Can I use this peptide for in vitro studies?

Yes, this peptide is suitable for various in vitro experiments aimed at understanding the mechanisms of beta-amyloid aggregation and its role in neurodegenerative conditions.

To explore more about our range of peptides, check our full catalog of peptides. Incorporate the [Gln22,Asn23]-beta-Amyloid (1-40) into your research for critical insights into Alzheimer’s pathology.

Related Products

• PKG Substrate [RKRSRAE], Glasstide